Arch Biopartners Inc. announces that Arch scientists have reported findings that identify key inflammation pathways in chronic kidney disease and C. difficile colitis.
The studies are the result of the scientists' ongoing research at the University of Calgary and are reported in the journals Gastroenterology and The Journal of the American Society of Nephrology.
Dr. Daniel Muruve, a principal scientist of Arch and co-author of the three papers, stated: "These findings are a key step in the Company's ongoing development of therapeutics for chronic kidney disease and C. difficile colitis."
Chronic kidney disease affects approximately 5-10 percent of the population in North America with annual health care costs in excess of 50 billion dollars. Patients with chronic kidney disease are at increased risk of heart disease, stroke and all-cause mortality. Currently there are very few specific treatments for patients with chronic kidney disease. Dr. Daniel Muruve and colleagues have identified important inflammatory pathways that cause chronic kidney damage. The paper by Vilaysane et al can be found here.
C. difficile are extremely toxic, super bacteria that are responsible for recent outbreaks and the majority of cases of hospital acquired diarrhea and inflammatory colitis. C. difficile are easily spread among hospitalized patients increasing the risk of major medical and surgical complications including death. C. difficile associated diseases increase the cost of health care by billions of dollars worldwide. Dr. Beck, Dr. Justin MacDonald and colleagues have identified two important pathways that control the host response to C. difficile infection in the gut. Papers by Ng et al and Hirota et al can be found here and here.